On this page
What did the U.S. partner bring?
Tristel is a UK infection-prevention business. It developed disinfectant products used with medical devices. In March 2018, it announced a manufacturing and marketing agreement with New Jersey-based Parker Laboratories for its Duo foam across the Americas. Parker already worked in the ultrasound market and had a distribution network.
The relationship continued into the launch of Tristel ULT, its ultrasound-probe disinfectant. Tristel’s FY2025 report describes Parker as its manufacturing and distribution partner, with a direct sales force as well as a nationwide network. An overseas business considering this route should identify the specific production and selling capabilities it needs from a partner.
The agreement was one step in a longer launch
Tristel’s June 2022 submission announcement reported five years of testing and data generation, with £2.8 million invested in the project and expensed. That is the company’s reported development spending at that date; it is not a budget for another business.
On 2 June 2023, the FDA granted De Novo classification for the prescription device Tristel Duo ULT. The stated uses cover high-level disinfection of endocavity transvaginal and transrectal ultrasound probes, and skin-surface transducers that may contact non-intact skin. Marketing remains subject to the order’s scope and controls. The grant does not establish compliance with every other applicable requirement.
| Milestone in the record | What an owner can establish from it |
|---|---|
| Partner agreement, March 2018 | A production and marketing relationship had been announced. |
| De Novo submission, June 2022 | The company had submitted a device application after reported testing and spending. |
| FDA grant, June 2023 | A decision for the named device and specified uses, subject to controls. |
The £108,000 figure is for FY2025
For the year ended 30 June 2025, Tristel reported North America royalty income of £108,000, compared with £74,000 in FY2024. Its report also described engagement with around 200 health systems and a priority of achieving deeper adoption within those accounts.
This is a historical FY2025 figure. The later FY2026 results report revenue for the wider Americas region, with a changed geographic reporting basis. They do not give a comparable North America royalty figure.
Keep those measures separate. The royalty figure is income reported by Tristel. It does not disclose Parker’s total customer sales, either company’s U.S. net profit, or the overseas owner’s return after support costs. Engagement with a health system is also a different measure from a paid order.
The October 2026 results make the next task explicit: converting regulatory access into routine use. Tristel described lengthy hospital evaluation and procurement cycles and an objective of generating repeat consumable revenue. Clearance, introductions, paid orders and repeat orders each need their own evidence.
Put a person and a budget against the remaining work
Tristel’s reports describe continuing investment in regulatory work, clinical evidence and commercial capability. Public announcements do not reveal the full private allocation of duties between the two companies. The table below is ELN’s planning exercise for your proposed deal; it is not a reconstruction of their contract.
| Work your launch needs | Question for management and the proposed partner |
|---|---|
| Product evidence and permitted claims | Who prepares, pays for and maintains the evidence and approvals for the exact U.S. product? |
| Production and supply | Who funds stock, checks quality and resolves supply interruptions? |
| Customer evaluation and purchasing | Who runs demonstrations, answers technical questions and gets the product onto a customer’s ordering system? |
| Repeat orders and parent support | Who follows up usage, collects the agreed payment data and budgets the overseas team’s time? |
Which job would delay your first repeat order?
Ask management to follow one target customer from introduction through evaluation, a paid first order and a repeat order. Record the responsible person, required evidence, cost and cash due before each step. Include work supplied by your overseas team.
Use the gaps to choose a next action: change the partner’s responsibilities, fund a missing role, narrow the first product offer or delay the commitment. A company’s experience can help frame those questions; its royalty income cannot establish what your own deal will earn.
Scope
- This is a documented commercial case, not an endorsement of either company or an assessment of today’s product compliance. Business spending, royalties and adoption commentary are company-reported.
- The complete commercial agreement, royalty calculation, partner customer sales, parent support costs and U.S. net profit were not established from these sources.
- The FDA decision cited concerns Tristel Duo ULT and its specified uses. It does not authorise another product, business or claim. ELN’s responsibility table and suggested next steps are editorial planning judgments.
Next step
Bring one customer-to-repeat-order plan to the next management meeting. Assign each job, its cost and the evidence required before funding the next step.
Terms used here
- Royalty income
- Income reported by the company under its commercial agreement. The contract determines the calculation; the amount is not the same as customer sales or net profit.
Sources & review notes
Tristel plc
Passage, dates and research notes
primary · Complete two-page company announcement; substantive body on PDF p1. Read manufacturing/marketing territory, distribution description, staged EPA/FDA plans and forward-looking qualification. Historical announcement, not the full agreement or evidence that approvals expected in 2018 were obtained.
a manufacturing and marketing agreement with Parker Laboratories Inc., USA
Read the retained full source in the stated scope on 15 November 2026. Company statements are attributed; the FDA order independently establishes its device-specific historical decision. Private contract terms, partner economics and U.S. net profit are not established.
Tristel plc, hosted by Parker Laboratories
Passage, dates and research notes
primary · Complete one-page issuer announcement. Read product and submission description, partner manufacturing/distribution, five years of testing/data and £2.8m expensed investment. Do not reuse its old FDA process timing, market superlatives or forward-looking state-approval forecasts.
We have made an investment of £2.8 million in the project which has all been expensed.
Read the retained full source in the stated scope on 15 November 2026. Company statements are attributed; the FDA order independently establishes its device-specific historical decision. Private contract terms, partner economics and U.S. net profit are not established.
U.S. Food and Drug Administration
Passage, dates and research notes
primary · Complete five-page FDA order. Read device-specific prescription indications on p1, class II determination p2, controls pp2–4, explicit other-requirements limitation and immediate-marketing scope p4. Article cites the historical grant, not present compliance with every FDA or state requirement.
subject to the general control provisions of the FD&C Act and the special controls identified in this order.
Read the retained full source in the stated scope on 15 November 2026. Company statements are attributed; the FDA order independently establishes its device-specific historical decision. Private contract terms, partner economics and U.S. net profit are not established.
Tristel plc
Passage, dates and research notes
primary · PDF pp7–8 (printed pp6–7), p15 (printed p14), p23 (printed p22): full North America/strategic context, partner sales force and distribution, £108k/FY2024 £74k royalty income, approximately 200 health-system engagements, continuing regulatory responsibilities and cash monitoring. Also read opening results context on PDF pp4–10. No inference about Parker customer sales, contract royalty rate or U.S. net profit.
revenue from royalty income increasing to
Read the retained full source in the stated scope on 15 November 2026. Company statements are attributed; the FDA order independently establishes its device-specific historical decision. Private contract terms, partner economics and U.S. net profit are not established.
Tristel plc, RNS announcement retained by FCA National Storage Mechanism
Passage, dates and research notes
primary · Full chairman/CEO strategy and North America sections, extracted lines1–293; revenue Note3 lines748–839 and full 1390-line HTML/text keyword scan (no royalty/royalties line). Specific reliance: lines79–81 and255–260 distinguish regulatory access from routine adoption, lengthy hospital procurement and repeat consumable objective. Note3 states end-customer rather than origin-of-sale geographic allocation and restated comparatives, with wider Americas revenue/PBT rather than a comparable North America royalty line. Do not relabel those regional measures as U.S. royalties or net profit.
US hospital systems are large and their evaluation and procurement cycles can be lengthy.
Read the retained full source in the stated scope on 15 November 2026. Company statements are attributed; the FDA order independently establishes its device-specific historical decision. Private contract terms, partner economics and U.S. net profit are not established.
Bookmark this guide or mark it as read.
Progress privacy
Saving is off by default. Without it, progress lasts only on this page. If you turn it on, this browser profile stores public content IDs and the progress you record. Anyone sharing the profile could see them. No plan inputs or contact details are included. Reset or export in learning settings.
This is a reading aid, not evidence of disclosure delivery, expertise or legal approval.